ArticleBMJ medicine2023
New and emerging treatments for myasthenia gravis.
Article in BMJ medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study.Journal of neurology · 2025Trial
- Real-world Treatment Patterns Among Patients with Generalized Myasthenia Gravis in the United States.Neurology and therapy · 2026Article
- Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis.Journal of managed care & specialty pharmacy · 2026Article
- Evaluation of steroid toxicity using the Glucocorticoid Toxicity Index-Metabolic Domains instrument in adults with myasthenia gravis: a real-world study in the USA.Journal of comparative effectiveness research · 2026Article
- Patient Perceptions of Needs and Expectations Regarding the Current Management of Myasthenia Gravis: A Biopsychosocial Study.Neurology and therapy · 2026Article
- Junctions in Jeopardy: the neuromuscular junction is a selective pathological target in Charcot-Marie-Tooth disease.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- Advancing Care in Myasthenia Gravis: What Can We Learn From the Multiple Sclerosis Community?Neurology and therapy · 2026Article
- Clinical Impact of High-Dose Corticosteroids on Healthcare Resource Utilization and Steroid-Related Complications in Patients with Myasthenia Gravis in Japan.Neurology and therapy · 2026Article
- Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.Therapeutic advances in neurological disorders · 2026Article
- Unexpected longevity in myasthenia gravis: a multi-state population-based comparison with multiple sclerosis and the U.S. population.Therapeutic advances in neurological disorders · 2026Article
- A Delphi consensus on integrating novel therapies into the management of generalized myasthenia gravis.Therapeutic advances in neurological disorders · 2026Article
- Medicare Part D Use and Costs for Immune-Mediated Neurologic Therapies.JAMA network open · 2025Article
- Patient journey and treatment pattern in myasthenia gravis: real-world data from the Brazilian public health system.Arquivos de neuro-psiquiatria · 2025Article
- Patient journey and treatment pattern in myasthenia gravis: real-world data from the Brazilian public health system.Arquivos de neuro-psiquiatria · 2025Observational
- Real-World Case Series of Ravulizumab Use in Patients with Myasthenia Gravis in Romania.Brain sciences · 2025Article
- Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data.Orphanet journal of rare diseases · 2025Article
- Myasthenia gravis in 2025: five new things and four hopes for the future.Journal of neurology · 2025Review
- Mapping the genetic landscape of immune-mediated disorders: potential implications for classification and therapeutic strategies.Frontiers in immunology · 2025Article
- Atypical Bulbar Myasthenia Gravis in an Elderly Male Unmasked by Levofloxacin: A Diagnostic Challenge.European journal of case reports in internal medicine · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.